China Resources Boya Bio pharmaceutical Group Co Ltd

The company maintains a strong liquidity position with a current ratio of 5.06, indicating a robust ability to meet short-term obligations. However, its free cash flow is negative at -426.83 million CNY, suggesting that capital expenditures are outpacing operating cash flow. The price-to-book ratio of 1.07 and a low debt-to-equity ratio of 0.01 reflect a conservative capital structure with minimal leverage. Profitability metrics show a return on equity of 1.52% and a return on assets of 1.31%, both below the industry median for pharmaceutical firms. The gross margin of 49.5% is in line with industry norms, but the operating margin of 5.25% is weak, indicating inefficiencies in cost management or pricing power. Geographically, the company's revenue is concentrated in China, with no disclosed international operations. Segment-wise, oncology and autoimmune disease treatments represent the primary revenue drivers, though the exact contribution of each segment is not specified in the available data. The company's revenue growth is modest, with a year-over-year increase of 3.2% in the latest reported period. Analysts project a mean price target of 28.55 CNY, implying a 79.9% upside from the current market price of 15.8 CNY. However, the absence of strong buy or buy ratings from analysts suggests limited near-term growth expectations. The risk assessment highlights a medium liquidity risk due to negative net cash after subtracting total debt. The dilution risk is low, with no significant dilution potential in the basic shares outstanding. The company has not issued additional shares recently, and no dilutive events are disclosed in the latest filings. Recent events include a 2026-04 regulatory update on biopharmaceutical approvals in China, which could impact the company's product pipeline. No material earnings surprises or management changes were disclosed in the latest quarterly reports.